Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

The QuickSwitch Quant HLA-A*02:01 Tetramer Kit can be used for determining the biological activity of a cancer vaccine.

Marc C Delcommenne, Olga Hrytsenko, Cynthia Tram, Genevieve Weir and Marianne M. Stanford
J Immunol May 1, 2017, 198 (1 Supplement) 79.27;
Marc C Delcommenne
1MBL International
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olga Hrytsenko
2Immunovaccine Inc., Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Tram
2Immunovaccine Inc., Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Genevieve Weir
2Immunovaccine Inc., Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianne M. Stanford
2Immunovaccine Inc., Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

We have devised a fast and user-friendly assay (QuickSwitch™ Quant) that can both help determine binding of novel peptides to MHC class I molecules and generate new specificity MHC class I tetramers for peptide specific T cell detection. This study aimed to determine whether the QuickSwitch™ Quant HLA-A*02:01 Tetramer Kit can also be used for evaluating the biological activity of a vaccine. The tested vaccine was DPX-Survivac, an ovarian cancer vaccine candidate which consists of several survivin peptide antigens that are each restricted to a different human class I allele. We sought to evaluate the specificity and sensitivity of the QuickSwitch™ Quant HLA-A* 02:01 Tetramer Kit-PE for assessing the biological activity of SurA2.M, an HLA-A2-restricted peptide, in DPX-Survivac. The complete vaccine also contains non-HLA-A2 restricted peptides, lipids and a polynucleotide adjuvant. We tested the detection of the peptide prepared individually in a buffered solution or in the DPX-Survivac vaccine prepared in an aqueous formulation. Results indicate that peptide exchange rate of SurA2.M is similar whether it is dissolved individually in a buffered solution or mixed with other components of the vaccine. Results also may be dependent on the affinity of the peptide for HLA-A2. Thus, by optimizing a concentration curve using individual peptides, the QuickSwitch™ Quant HLA-A*02:01 Tetramer Kit can be used to quantify the concentration of HLA-A2 restricted peptides in simple solutions or more complex formulations.

  • Copyright © 2017 by The American Association of Immunologists, Inc.
Previous
Back to top

In this issue

The Journal of Immunology
Vol. 198, Issue 1 Supplement
1 May 2017
  • Table of Contents
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The QuickSwitch Quant HLA-A*02:01 Tetramer Kit can be used for determining the biological activity of a cancer vaccine.
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The QuickSwitch Quant HLA-A*02:01 Tetramer Kit can be used for determining the biological activity of a cancer vaccine.
Marc C Delcommenne, Olga Hrytsenko, Cynthia Tram, Genevieve Weir, Marianne M. Stanford
The Journal of Immunology May 1, 2017, 198 (1 Supplement) 79.27;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The QuickSwitch Quant HLA-A*02:01 Tetramer Kit can be used for determining the biological activity of a cancer vaccine.
Marc C Delcommenne, Olga Hrytsenko, Cynthia Tram, Genevieve Weir, Marianne M. Stanford
The Journal of Immunology May 1, 2017, 198 (1 Supplement) 79.27;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Info & Metrics

Related Articles

Cited By...

More in this TOC Section

  • Development of a curative therapeutic vaccine (TheraVac) for the treatment of large established tumors
  • Genetic linkage analysis of cancer vaccine response in Diversity Outbred mice
  • Targeting adenosine A2A receptors to improve vaccine efficacy
Show more Novel Strategies for Cancer Vaccines

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606